Esophageal Cancer (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer – Drugs In Development, 2021, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 99, 114, 13, 43, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 6, 4, 1 and 4 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).

– The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

Adaptimmune Therapeutics Plc

ADC Therapeutics SA

Advanced Accelerator Applications SA

Advenchen Laboratories LLC

Affimed GmbH

AIMM Therapeutics BV

Akeso Inc

Alphamab Oncology

Ambrx Biopharma Inc

amcure GmbH

AMI Onco Theranostics LLC

Anhui Anke Biotechnology (Group) Co Ltd

Anhui Kedgene Biotechnology Co Ltd

Apexigen Inc

Apollomics Inc

Arcus Biosciences Inc

Arog Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Esophageal Cancer - Overview

Esophageal Cancer - Therapeutics Development

Esophageal Cancer - Therapeutics Assessment

Esophageal Cancer - Companies Involved in Therapeutics Development

Esophageal Cancer - Drug Profiles

Esophageal Cancer - Dormant Projects

Esophageal Cancer - Discontinued Products

Esophageal Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Esophageal Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Esophageal Cancer – Pipeline by AbbVie Inc, 2021

Esophageal Cancer – Pipeline by Adaptimmune Therapeutics Plc, 2021

Esophageal Cancer – Pipeline by ADC Therapeutics SA, 2021

Esophageal Cancer – Pipeline by Advanced Accelerator Applications SA, 2021

Esophageal Cancer – Pipeline by Advenchen Laboratories LLC, 2021

Esophageal Cancer – Pipeline by Affimed GmbH, 2021

Esophageal Cancer – Pipeline by AIMM Therapeutics BV, 2021

Esophageal Cancer – Pipeline by Akeso Inc, 2021

Esophageal Cancer – Pipeline by Alphamab Oncology, 2021

Esophageal Cancer – Pipeline by Ambrx Biopharma Inc, 2021

Esophageal Cancer – Pipeline by amcure GmbH, 2021

Esophageal Cancer – Pipeline by AMI Onco Theranostics LLC, 2021

Esophageal Cancer – Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, 2021

Esophageal Cancer – Pipeline by Anhui Kedgene Biotechnology Co Ltd, 2021

Esophageal Cancer – Pipeline by Apexigen Inc, 2021

Esophageal Cancer – Dormant Projects, 2021

Esophageal Cancer – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Esophageal Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports